Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Futó vizsgálatok

• Toboroz

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

  NCT06191263· 2. fázis· Ryvu Therapeutics SA· Forrás

• Fut, nem toboroz

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· 3. fázis· TransThera Sciences (Nanjing), Inc.· Forrás

• Toboroz

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Fut, nem toboroz

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

  NCT04996017· 3. fázis· Gruppo Oncologico Italiano di Ricerca Clinica· Forrás

• Fut, nem toboroz

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Janssen Pharmaceutica N.V., Belgium· Forrás

• Fut, nem toboroz

  A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

  NCT04586231· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

  NCT04502394· 1/2. fázis· Kartos Therapeutics, Inc.· Forrás

• Fut, nem toboroz

  A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

  NCT04023526· 2. fázis· OncoVerity, Inc.· Forrás

• Fut, nem toboroz

  Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

  NCT03595592· 3. fázis· Fondazione Michelangelo· Forrás

• Fut, nem toboroz

  First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037· 1/2. fázis· Genmab· Forrás

• Fut, nem toboroz

  Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

  NCT03386513· 1/2. fázis· AbbVie· Forrás

• Fut, nem toboroz

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· 3. fázis· UNICANCER· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Akut mieloid leukémia (AML)2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Tüdőrák2 toboroz
• Áttétes emlőrák1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Mezotelióma1 toboroz

Lezárt vizsgálatok

• Visszavonták

  To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

  NCT05212701· 2. fázis· Dompé Farmaceutici S.p.A· Forrás

• Leállították

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· 2. fázis· Taiho Oncology, Inc.· Forrás

• Lezárult

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· 3. fázis· Stemline Therapeutics, Inc.· Forrás

• Lezárult

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

  NCT03596866· 3. fázis· Takeda· Forrás

• Leállították

  Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· 3. fázis· Eisai Inc.· Forrás

• Lezárult

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· 2. fázis· Incyte Corporation· Forrás

• Lezárult

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· 3. fázis· Pharmacyclics LLC.· Forrás

• Leállították

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· 1/2. fázis· Sun Pharma Advanced Research Company Limited· Forrás

• Lezárult

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· 2. fázis· Iovance Biotherapeutics, Inc.· Forrás

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Áttétes emlőrák17 munka · 4 vizsgálat
• Mieloproliferatív neopláziák17 munka · 1 vizsgálat
• Krónikus limfoid leukémia (CLL)11 munka · 3 vizsgálat
• Krónikus mieloid leukémia (CML)6 munka · 1 vizsgálat